Clarivate Expands Access to Trusted Regulatory Intelligence Within Claude

Rhea-AI Summary

Clarivate (NYSE: CLVT) announced on March 10, 2026 that Cortellis Regulatory Intelligence (CRI) will integrate with Anthropic's Claude via the open Model Context Protocol (MCP).

This integration embeds authoritative regulatory content into Claude workflows, giving life sciences teams access to referenced regulatory answers and enabling CRI to work alongside internal data and agents.

Positive

• CRI integrated with Claude via the open Model Context Protocol
• Authoritative regulatory content embedded directly into customer AI workflows
• CRI MCP is available to Clarivate CRI and Claude customers, enabling agents to combine CRI with internal data

Negative

• None.

News Market Reaction – CLVT

+1.15%

1 alert

+1.15% Session close to close

$1.69B Market Cap

0.0x Rel. Volume

In the Mar 10 session, CLVT gained 1.15%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends Clarivate’s Cortellis Regulatory Intelligence into Claude via the Model Co...

Analysis

This announcement extends Clarivate’s Cortellis Regulatory Intelligence into Claude via the Model Context Protocol, giving life sciences and regulatory teams AI-assisted access to trusted regulatory content. It builds on earlier AI launches in regulatory and workflow tools, reinforcing a strategy of pairing proprietary data with AI reasoning. Investors may watch adoption by CRI and Claude customers, evidence of workflow efficiency gains, and how this integration complements Clarivate’s broader AI-enabled product roadmap.

Key Figures

Announcement date: March 10, 2026

1 metrics

Announcement date March 10, 2026 Date of Clarivate–Claude regulatory intelligence integration news

Previous AI Reports

5 past events · Latest: Feb 03 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 03	AI webinar launch	Positive	-20.4%	Webinar showcasing Clarivate proprietary data and AI capabilities across workflows.
Jan 22	AI academic assistant	Positive	+3.6%	Launch of Clarivate Nexus embedding academic content into AI and campus tools.
Jan 15	AI platform upgrade	Positive	+0.6%	MongoDB integrating Voyage AI models to enhance retrieval accuracy in Atlas.
Dec 04	Regulatory AI assistant	Positive	+0.3%	Launch of Cortellis Regulatory Intelligence AI Assistant for safety and compliance.
Nov 24	AI patent tool launch	Positive	+0.9%	Derwent Patent Monitor debut using AI on proprietary patent data to speed reviews.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-related announcements have generally seen modest to mixed price reactions, with one notable negative outlier despite positive product news.

Recent Company History

Recent AI-tagged news for Clarivate shows a steady build-out of AI-enabled products across research, academic, regulatory, and IP workflows. Since Nov 24, 2025, launches like Derwent Patent Monitor and the Cortellis Regulatory AI Assistant, plus the Feb 3, 2026 AI webinar and the Jan 22, 2026 Nexus announcement, all emphasized embedding proprietary data into AI tools. Today’s Claude integration continues that theme by extending Cortellis Regulatory Intelligence into external AI ecosystems used by life sciences customers.

Key Terms

regulatory intelligence, pharmacovigilance, model context protocol (mcp), regulatory affairs, +1 more

5 terms

regulatory intelligence regulatory

"integrate Clarivate's proprietary regulatory intelligence with Claude's AI reasoning"

Regulatory intelligence is the process of gathering, analyzing, and understanding rules and policies set by governments and authorities that impact financial markets and businesses. It helps investors and companies stay informed about upcoming or changing regulations, much like how a navigator uses maps and signals to avoid obstacles and reach a destination safely. This knowledge is crucial for making informed decisions and managing risks in a constantly evolving regulatory environment.

pharmacovigilance medical

"provides regulatory affairs, pharmacovigilance and life sciences teams with direct access"

Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.

model context protocol (mcp) technical

"integrated into Anthropic's Claude through the open Model Context Protocol (MCP)"

The Model Context Protocol (MCP) is a system that helps financial models understand and share information about market conditions and data. It’s like a common language that ensures different tools and models work together smoothly, making predictions and decisions more accurate and consistent.

regulatory affairs regulatory

"provides regulatory affairs, pharmacovigilance and life sciences teams with direct access"

Regulatory affairs is the team and processes that secure and maintain government approvals, permits, and ongoing compliance for a company’s products, such as drugs, medical devices, or financial offerings. Think of them as the navigator and permit office that prepares submission paperwork, answers regulator questions, and monitors safety and labeling after launch. Their work matters to investors because regulatory timing, costs, and approval risk directly affect a product’s ability to reach markets and generate revenue.

ai workflows technical

"access authoritative content within their AI workflows and make more informed decisions"

AI workflows are the step-by-step processes that use artificial intelligence to take raw data, transform it, run models, and produce decisions or outputs — much like an automated assembly line that turns parts into finished products. For investors, they matter because well-designed AI workflows can lower costs, speed product development, scale services, and create competitive advantages, while poor design can introduce errors, higher costs, or regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Advancing Clarivate strategy to extend proprietary intelligence into enterprise AI ecosystems

Bringing Clarivate domain-specific regulatory insights into Claude to support life sciences workflows

LONDON, March 10, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced they will integrate Clarivate's proprietary regulatory intelligence with Claude's AI reasoning capabilities. The collaboration gives biopharma, biotech, medtech and clinical research organizations intelligent, context-aware access to authoritative regulatory data within the AI workflows they already use.

Cortellis Regulatory Intelligence (CRI) data and insights will be integrated into Anthropic's Claude through the open Model Context Protocol (MCP). This MCP-enabled connection embeds authoritative regulatory content directly into customer workflows- combining Claude's natural language understanding and reasoning with Clarivate's industry-validated sources to deliver accurate, referenced answers that support faster, more confident regulatory decision-making.

The new CRI MCP provides regulatory affairs, pharmacovigilance and life sciences teams with direct access to Clarivate regulatory intelligence, delivering accurate, referenced answers grounded in industry-validated sources. The CRI MCP is available to customers of Clarivate CRI and Claude.

Through this integration, Clarivate is extending its regulatory intelligence into the AI environments customers already use, expanding the ecosystems that inform critical decisions. With this connection to Claude, customers can build agents that combine CRI with internal data and approved external sources, enabling regulatory intelligence to work alongside internal data to monitor changes and support decision-making.

Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: "This advances our strategy to extend Clarivate intelligence into AI ecosystems where critical decisions are made. By bringing Cortellis Regulatory Intelligence into Claude, we are expanding the reach of our trusted regulatory insights. This enables Clarivate life sciences customers to access authoritative content within their AI workflows and make more informed decisions that help bring safer, more effective therapies to patients."

Building on the recent launch of the CRI AI Assistant, the integration expands anticipatory intelligence and intelligent automation across regulatory workflows. To learn more about Cortellis Regulatory Intelligence, visit: Cortellis Regulatory Intelligence.

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

Media Contact:

Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-expands-access-to-trusted-regulatory-intelligence-within-claude-302708813.html

SOURCE Clarivate Plc

FAQ

What does the Clarivate and Anthropic Claude integration mean for CLVT customers?

It provides direct, in-workflow access to Clarivate regulatory intelligence within Claude AI. According to Clarivate, CRI content will be embedded via the MCP to deliver referenced regulatory answers that teams can use alongside internal data to support decision-making.

How will Cortellis Regulatory Intelligence be delivered inside Claude for CLVT users?

CRI will be integrated into Claude through the open Model Context Protocol (MCP). According to Clarivate, the MCP-enabled connection embeds industry-validated regulatory content directly into customer workflows for accurate, referenced answers.

Which life sciences teams benefit from Clarivate's CRI integration with Claude (CLVT)?

Regulatory affairs, pharmacovigilance, and life sciences teams gain direct access to CRI within AI workflows. According to Clarivate, the integration supports faster, more confident regulatory decision-making with context-aware, authoritative content.

Is the CRI MCP available now to Clarivate (CLVT) and Claude customers?

Yes, the CRI MCP is available to customers of Clarivate CRI and Claude. According to Clarivate, customers can access regulatory intelligence inside Claude and build agents that combine CRI with internal and approved external sources.

How does the Clarivate (CLVT) integration with Claude affect regulatory decision-making?

It aims to speed and improve regulatory decisions by providing referenced, authoritative answers inside AI workflows. According to Clarivate, combining CRI with Claude's reasoning enables more confident, context-aware regulatory guidance alongside internal data.